Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Brueckl WM, et al. Among authors: ulm b. Transl Lung Cancer Res. 2021 Jul;10(7):3093-3105. doi: 10.21037/tlcr-21-197. Transl Lung Cancer Res. 2021. PMID: 34430350 Free PMC article.
Goal-directed Perioperative Albumin Substitution Versus Standard of Care to Reduce Postoperative Complications: A Randomized Clinical Trial (SuperAdd Trial).
Schaller SJ, Fuest K, Ulm B, Schmid S, Bubb CAB, Eckstein HH, von Eisenhart-Rothe R, Friess H, Kirchhoff C, Luppa P, Blobner M, Jungwirth B. Schaller SJ, et al. Among authors: ulm b. Ann Surg. 2024 Mar 1;279(3):402-409. doi: 10.1097/SLA.0000000000006030. Epub 2023 Jul 21. Ann Surg. 2024. PMID: 37477023 Clinical Trial.
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Brueckl WM, et al. Among authors: ulm b. Clin Med Insights Oncol. 2020 Aug 19;14:1179554920951358. doi: 10.1177/1179554920951358. eCollection 2020. Clin Med Insights Oncol. 2020. PMID: 32884390 Free PMC article.
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).
Tufman A, Neumann J, Manapov F, Sellmer L, Jung A, Kauffmann-Guerrero D, Kahnert K, Mertsch P, Borgmeier A, Semrau S, Rittmeyer A, Ulm B, Ulm K, Flentje M, Fietkau R, Huber RM. Tufman A, et al. Among authors: ulm k, ulm b. Lung Cancer. 2021 Oct;160:17-27. doi: 10.1016/j.lungcan.2021.07.008. Epub 2021 Jul 20. Lung Cancer. 2021. PMID: 34371299
SARS-CoV-2 serology increases diagnostic accuracy in CT-suspected, PCR-negative COVID-19 patients during pandemic.
Schneider J, Mijočević H, Ulm K, Ulm B, Weidlich S, Würstle S, Rothe K, Treiber M, Iakoubov R, Mayr U, Lahmer T, Rasch S, Herner A, Burian E, Lohöfer F, Braren R, Makowski MR, Schmid RM, Protzer U, Spinner C, Geisler F. Schneider J, et al. Among authors: ulm k, ulm b. Respir Res. 2021 Apr 23;22(1):119. doi: 10.1186/s12931-021-01717-9. Respir Res. 2021. PMID: 33892720 Free PMC article.
99 results